Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs. The iLet system has been cleared by the U.S. Food and Drug Administration for use by people with type 1 diabetes and is designed to work with compatible continuous glucose monitoring technology.

Beta Bionics grew out of research into a “bionic pancreas” led by Dr. Edward Damiano, an engineer and researcher whose work was motivated in part by his son’s diagnosis with type 1 diabetes. The company’s commercial activities have primarily focused on the United States, where it markets its insulin-delivery technology through healthcare and diabetes-care channels. Its leadership includes co-founder and Chief Executive Officer Sean Saint, who has overseen the company’s efforts to advance and commercialize its automated insulin-delivery platform.

Key Stats

• Today's Range: $16.60 to $17.60
• 50-Day Range: $14.11 to $22.81
• 52-Week Range: $8.80 to $32.71
• Volume: 1.33 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: $778.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Moderate Buy

Beta Bionics Stock Analysis - MarketRank™

Beta Bionics scored higher than 65% of companies evaluated by MarketBeat, and ranked 301st out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 9 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Beta Bionics has a consensus price target of $24.00, representing about 41.3% upside from its current price of $16.99.

Amount of Analyst Coverage

Beta Bionics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Beta Bionics are expected to decrease in the coming year, from ($2.02) to ($2.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beta Bionics is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beta Bionics is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beta Bionics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.19% of the float of Beta Bionics has been sold short.

Short Interest Ratio / Days to Cover

Beta Bionics has a short interest ratio ("days to cover") of 3.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beta Bionics has recently decreased by 43.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beta Bionics does not currently pay a dividend.

Dividend Growth

Beta Bionics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.19

News Sentiment

Beta Bionics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 39 news articles for Beta Bionics this week, compared to 9 articles on an average week.

Search Interest

Only 1 people have searched for BBNX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,907,034.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Beta Bionics is held by insiders.

Percentage Held by Institutions

Beta Bionics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: www.betabionics.com
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 423
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Beta Bionics: $24.00
• High Price Target: $32.00
• Low Price Target: $16.00
• Potential Upside/Downside: +38.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.20 million
• Net Margins: -61.31%
• Pretax Margin: -61.31%
• Return on Equity: -26.30%
• Return on Assets: -23.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.88
• Quick Ratio: 7.96

Sales & Book Value

• Annual Sales: $119.01 million
• Price / Sales: 6.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.53 per share
• Price / Book: 2.65

Miscellaneous

• Outstanding Shares: 44,990,000
• Free Float: 42,606,000
• Market Cap: $778.78 million
• Optionable: N/A
• Beta: 3.39